Rate My Professor Klaus-Martin Schulte

Professor Klaus-Martin Schulte, MD, FRCS, FRACS, serves as Professor and Chair of Transdisciplinary Health Research at the Australian National University since 2024, succeeding his role as Professor and Chair of Surgery at the same institution from 2014 to 2024. He earned his MD and PhD from the University of Duisburg-Essen, with additional training periods at Harvard Medical School in 1990, Baylor College of Medicine Houston in 1989, and the University of Paris and Collège de France from 1985 to 1987. Currently, he is also Consultant Endocrine Surgeon at King’s College Hospital London since 2004 on a part-time basis since 2014, Reader of Endocrine Surgery at King’s College London since 2012, and Professor extraordinarius of Surgery at Heinrich Heine University Düsseldorf since 2010. Earlier in his career, Schulte was Lead Clinician for Endocrine Surgery and for Emergency General and Major Trauma Surgery at King’s College Hospital from 2007 to 2012, Programme Director of Surgery at University of Düsseldorf from 2001 to 2003 managing 6000 surgeries annually, and Head of the Laboratory of Surgery and Supervisor of Gene Technology at the same university since 1998. He received full personal grants from the German National Scholarship Foundation (1985-1990), Alfried Krupp von Bohlen und Halbach Foundation (1991-1992), and German Research Foundation (1998-2000), along with the Oberdisse Award of the NRW Society of Endocrinology in 1998, Dr. Günther Wille Award in 1999, von Langenbeck Award of the German Society of Surgery in 2002, and ongoing clinical excellence awards at King’s College Hospital.

Schulte leads the Schulte Group in Systems Biology of Cancer at the John Curtin School of Medical Research, Division of Genome Sciences and Cancer, investigating therapy options from the nucleolar stress response, Indigenous pharmacogenomics with the National Centre for Indigenous Genomics, space health through microwearables with the ANU Institute of Space, and therapeutic vulnerabilities in fusion gene-driven sarcomas. His research specializations include immune therapy of cancer, endocrine cancers such as pheochromocytoma, paraganglioma, and parathyroid cancer, growth regulation of benign endocrine tissues, lipidomics, and strategies for parathyroid hormone replacement. Notable publications comprise 'Castleman's disease—a two compartment model of HHV8 infection' (Nature Reviews Clinical Oncology, 2010), 'Margin Free Resection Achieves Excellent Long Term Outcomes in Parathyroid Cancer' (Cancers, 2023), 'Cell death and barrier disruption by clinically used iodine concentrations' (Life Science Alliance, 2023), and 'Defining the feasibility of same day adrenalectomy—A prospective matched cohort study' (Surgery Open Science, 2023). With 3352 citations and an h-index of 32 across 96 articles, 14 reviews, and 6 book chapters, his contributions significantly influence the field. As Chief Investigator A, he directs major funded projects including the MRFF grant for Indigenous pharmacogenomics (2023-2026) and the iLAuNCH Trailblazer program for space health (2023-2027).